Illumina agrees to buy cancer-detection start-up Grail for $8bn
Grail, whose list of high-profile investors includes Bill Gates and Jeff Bezos, is developing a blood test that aims to detect multiple cancers
Genetic sequencing giant Illumina has agreed to acquire Grail in a deal valuing the cancer-detection start-up at $8bn.
Grail shareholders will receive $3.5bn in cash and $4.5bn in Illumina common stock, the companies said in a statement on Monday. Both companies’ boards of directors have approved the transaction.
Illumina is a dominating player in DNA sequencing. Grail, whose list of high-profile investors includes Bill Gates and Jeff Bezos, is developing a blood test that aims to detect multiple cancers far earlier than is now possible. The deal will allow Illumina to further expand its technologies in diagnostics, a potentially multimillion-dollar industry.
“We have an important opportunity to introduce routine and broadly available blood-based screening that enables early cancer detection when treatment can be more effective and less costly,” Illumina CEO Francis DeSouza said in the statement.
Announcement of the deal, though, drove the San Diego-based company’s shares down 6.8% to $275.32 in New York trading. For Illumina investors “there will be convincing to do”, said Doug Schenkel, a Cowen & Company analyst, after the deal was announced.
“We don’t see the clear fit for acquiring a company that is still at a stage where clinical studies and clinical product development are still critical and will be for years,” he wrote in a research note, and “would benefit from true clinical commercial infrastructure/reach that does not really exist at Illumina.”
Grail was founded by Illumina, which holds about 12% of Grail’s shares on a fully diluted basis, according to the statement. It was later spun out as a stand-alone company.
Grail investors aside from Illumina will receive about $7.1bn. Shareholders will also be entitled to future payments representing a tiered single-digit percentage of certain Grail-related revenues.
The company grew out of a discovery at Illumina that signs of cancer were detectable in maternal blood samples. Known as “liquid biopsies”, such tests are a long-sought goal in the world of biomedical research, but developing them is complicated. Tests must look for many different markers that may signal different types of tumours, and also successfully avoid false positives.
Grail filed for an initial public offering in September. As a private company Grail has raised more than $1.9bn, regulatory filings show. Its much-touted test was planed to launch in 2021.
Data published by the company has suggested it can detect more that 50 types of cancer and that the test resulted in false positives less than 1% of the time. Illumina, which already has a small business selling diagnostic tests for genetic diseases and cancer therapy identification, will be tasked with bringing Grail’s test to market.
Illumina is also the supplier of the sequencers that Menlo Park, California-based Grail uses for performing its genomic tests. Bringing the two companies back together would put the testing and sequencing under one roof. Illumina’s sequencing business still accounts for the vast majority of its revenue.
The success of the Grail acquisition may hinge on the company’s ability to get insurers to pay for the test.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.